Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 495

1.
2.

CpG or IFN-α are more potent adjuvants than GM-CSF to promote anti-tumor immunity following idiotype vaccine in multiple myeloma.

Hong S, Qian J, Li H, Yang J, Lu Y, Zheng Y, Yi Q.

Cancer Immunol Immunother. 2012 Apr;61(4):561-71. doi: 10.1007/s00262-011-1123-2. Epub 2011 Oct 15.

3.

Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients.

Yi Q, Szmania S, Freeman J, Qian J, Rosen NA, Viswamitra S, Cottler-Fox M, Barlogie B, Tricot G, van Rhee F.

Br J Haematol. 2010 Sep;150(5):554-64. doi: 10.1111/j.1365-2141.2010.08286.x. Epub 2010 Jul 7.

4.
5.

Dendritic cell vaccine but not idiotype-KLH protein vaccine primes therapeutic tumor-specific immunity against multiple myeloma.

Wang S, Hong S, Wezeman M, Qian J, Yang J, Yi Q.

Front Biosci. 2007 May 1;12:3566-75.

PMID:
17485322
6.

Tumor cell lysate-pulsed dendritic cells are more effective than TCR Id protein vaccines for active immunotherapy of T cell lymphoma.

Gatza E, Okada CY.

J Immunol. 2002 Nov 1;169(9):5227-35. Erratum in: J Immunol. 2003 May 15;170(10):following 5332.

7.
8.

Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides.

Curti A, Tosi P, Comoli P, Terragna C, Ferri E, Cellini C, Massaia M, D'Addio A, Giudice V, Di Bello C, Cavo M, Conte R, Gugliotta G, Baccarani M, Lemoli RM.

Br J Haematol. 2007 Nov;139(3):415-24.

PMID:
17910631
9.

Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects.

Titzer S, Christensen O, Manzke O, Tesch H, Wolf J, Emmerich B, Carsten C, Diehl V, Bohlen H.

Br J Haematol. 2000 Mar;108(4):805-16.

PMID:
10792287
11.

Tumor cells loaded with α-galactosylceramide promote therapeutic NKT-dependent anti-tumor immunity in multiple myeloma.

Hong S, Lee H, Jung K, Lee SM, Lee SJ, Jun HJ, Kim Y, Song H, Bogen B, Choi I.

Immunol Lett. 2013 Nov-Dec;156(1-2):132-9. doi: 10.1016/j.imlet.2013.10.002. Epub 2013 Oct 19.

PMID:
24148970
12.

Induction of cellular immune responses in patients with stage-I multiple myeloma after vaccination with autologous idiotype-pulsed dendritic cells.

Röllig C, Schmidt C, Bornhäuser M, Ehninger G, Schmitz M, Auffermann-Gretzinger S.

J Immunother. 2011 Jan;34(1):100-6. doi: 10.1097/CJI.0b013e3181facf48.

PMID:
21150718
13.
14.
15.

Immunotherapy using dendritic cells against multiple myeloma: how to improve?

Nguyen-Pham TN, Lee YK, Kim HJ, Lee JJ.

Clin Dev Immunol. 2012;2012:397648. doi: 10.1155/2012/397648. Epub 2012 Mar 15. Review.

16.
17.

Myeloma cell line-derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma.

Qian J, Hong S, Wang S, Zhang L, Sun L, Wang M, Yang J, Kwak LW, Hou J, Yi Q.

Blood. 2009 Oct 29;114(18):3880-9. doi: 10.1182/blood-2009-06-227355. Epub 2009 Aug 4.

18.

Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma.

Tatsumi T, Takehara T, Kanto T, Miyagi T, Kuzushita N, Sugimoto Y, Jinushi M, Kasahara A, Sasaki Y, Hori M, Hayashi N.

Cancer Res. 2001 Oct 15;61(20):7563-7.

19.

Idiotype protein-pulsed dendritic cells produce strong anti-myeloma effects after syngeneic stem cell transplantation in mice.

Zeis M, Frenzke H, Schmitz N, Uharek L, Steinmann J.

Bone Marrow Transplant. 2002 Feb;29(3):213-21.

20.
Items per page

Supplemental Content

Write to the Help Desk